INTRODUCTION
Myeloid-derived suppressor cells (MDSCs) have emerged as a significant population involved in tumor-associated immunosuppression 1 and immune responses during stress, such as trauma and infection. 2 Overall, MDSCs represent a heterogeneous population of myeloid cells with a mainly immature but in certain cases mixed-maturation phenotype. 3 In contrast to their murine CD11b þ Gr1 þ counterpart, human MDSCs lack specific surface markers and are classified primarily based on their functional (suppressive) properties. 4 The CCAAT-enhancer protein b (C/EBPb) has been suggested as an MDSC-determining transcription factor 5 similar to FOXP3 in regulatory T cells (Tregs). In fact, reports regarding C/EBPb expression in human MDSCs have been inconsistent so far. [5] [6] [7] Differentiation arrest at various levels of myeloid development, in conjunction with the variety of factors capable of governing MDSC phenotype and function, might account for the observed diversity. 1, 4 However, two main human MDSC subsets are proposed: the monocytic and granulocytic MDSCs. 8, 9 These cell compartments can be mutually exclusive or in certain cases overlap as, for example, observed in very immature CD33 þ lineage neg HLA-DR low/neg myeloid cell fractions that were composed of both monocytic and granulocytic cells. 10 Several mechanisms have been described to contribute to the T-cell-suppressive activity of these cells. Among others, they involve L-arginine depletion by arginase 1 (ARG1) and the inducible nitric oxidase (iNOS), 3 generation of reactive oxygen species (ROS), 11 release of TGF-b 12 and interleukin-10 (IL-10), 13, 14 cysteine sequestration, 15 and Treg-induction. 12 One of the few well-characterized human MDSC-subsets is the monocytic CD14 þ cells with low levels or lack of the antigenpresenting HLA-DR molecules (CD14 þ HLA-DR low/neg cells). They have been described in several malignancies including melanoma, 3 prostate cancer, 16 ovarian cancer, 13 hepatocellular cancer 12 and B-cell non-Hodgkin's lymphoma. 17 They impede T-cell function through ARG1, 3, 17 IL-10 13,14 and Treg induction. 12 Not only cells retrieved from cancer patients but also CD14 þ HLA-DR low/neg cells isolated from healthy donors (HDs) are immunoregulatory (that is, by inducing Tregs), 18 suggesting that MDSCs, similar to Tregs, limit the extent and duration of immune responses.
Based on their suppressive function, MDSCs attract growing interest from the field of inflammatory disorders, including graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). In preclinical mouse models, MDSCs have been reported to expand during allo-HSCT 19 and MDSCs frequencies were associated with reduced lethality. 20 Notably, adoptive transfer of MDSCs antagonized GVHD-related mortality in a fully major histocompatibility complex-mismatched HSCT model while preserving the graftversus-tumor (GVT) effects. 21 In this study, we investigated whether MDSCs can be found in allo-HSCT patients during the phase of immune reconstitution. 22 We hypothesized that tissue damage following (radio-) chemotherapy as well as cytokines released from the cell transfer and subsequent immune (allo-) reactions create a (cytokine-) milieu that favors the generation of MDSCs.
We report the characterization of CD14 þ HLA-DR low/neg cells that accumulate in patients after allo-HSCT-especially during acute GHVD of higher grade. Their frequency correlated significantly with serum levels of IL-6 and granulocyte colonystimulating factor (G-CSF), both of which are associated with MDSC induction. 6, 7, 23 They suppressed proliferation of autologous T cells in an indoleamine 2,3-dioxygenase (IDO)-dependent manner. Furthermore, inhibiting IDO led to an enhanced IFN-g release and CD3z-chain expression on T cells, altogether suggesting that IDO þ CD14 þ HLA-DR low/neg cells contribute to T-cell dysfunction after allo-HSCT.
Overall, increased CD14 þ HLA-DR low/neg cell levels could represent an inherent response to the inflammatory state after allo-HSCT, in agreement with previous reports describing an augmented IDO activity in patients with GVHD. 24, 25 
PATIENTS AND METHODS Patients
This study was approved by the ethics committee of the Karolinska University Hospital (Stockholm, Sweden) and the University Hospital of Erlangen-Nuremberg (Erlangen, Germany). Peripheral blood was retrieved-in some cases more than once-during routine examinations from 51 patients following allo-HSCT (range: day þ 26 to day þ 379) irrespective of underlying disease, donor type, conditioning and GVHD prophylaxis. All patients and/or their parents signed informed consent in accordance to the Declaration of Helsinki. The median age of the patients was 50 years (range: 15-72 years) and the gender distribution was 30 males and 21 females. Indications for allo-HSCT were acute myeloid leukemia (n ¼ 20), chronic lymphoblasic leukemia (n ¼ 7), acute lymphoblastic leukemia (n ¼ 6), myelodysplastic syndrome (n ¼ 5), non-Hodgkin's lymphoma (n ¼ 4), chronic myeloproliferative disorder (n ¼ 5) and other hemato-oncological or immunological diseases (n ¼ 4). Patients received grafts from HLA-identical siblings (n ¼ 10) or unrelated donors (n ¼ 33), haplo-identical family members (n ¼ 4), cord blood (n ¼ 3) or HLAmismatched unrelated donors (n ¼ 1) following standard (n ¼ 18) or reduced intensity (n ¼ 33) conditioning. The majority of patients (33/51) received a calcineurin inhibitor and methotrexate as GVHD prophylaxis. Antithymocyte globulin was given to 37 patients. Chimerism analysis was performed routinely in bead-isolated CD33 þ myeloid cells from the patients' peripheral blood (n ¼ 42) using PCR amplification of variable number of tandem repeats as described in detail previously. 26 For healthy controls, peripheral blood was obtained from volunteers from the Karolinska University Hospital with the donors' informed consent.
Reagents
RPMI 1640 cell-medium, fetal bovine serum and trypan blue (0.4%) were purchased from Invitrogen (Carlsbad, CA, USA); dimethyl sulfoxide, penicillin-streptomycin, IFN-a, phorbol 12-myristate 13-acetate (PMA) and carboxyfluorescein succinimidyl ester (CFSE) from Sigma-Aldrich (St Louis, MO, USA).
Cell isolation
Peripheral blood mononuclear cells (PBMCs) collected at several time points after allo-HSCT, respectively, from HDs (n ¼ 31) were isolated by density gradient-based Ficoll-Paque (GE Healthcare, Waukesha, WI, USA) or Lymphoprep (Medinor AB, Lidingö , Sweden) and stored in liquid nitrogen until further processing. CD3 þ T cells and CD14 þ HLA-DR neg/low cells were isolated by magnetic bead separation according to manufacturer's instructions using CD3, CD14 and HLA-DR microbeads (Milenyi Biotec, Bergisch Gladbach, Germany) as described in detail elsewhere. 3 Purity of CD14 þ HLA-DR low/neg cells from patients and healthy controls was 85-90% (Supplementary Figure 1) .
T-cell proliferation assay
To determine the suppressive capacity of MDSCs, 50 000 autologous T cells were co-cultured in different ratios with MDSCs (1:0, 2:1, 4:1 and 8:1) for 5 days in the presence of anti-CD2/CD3/CD28-stimulating beadcoupled antibodies (Miltenyi Biotec) in a one bead per T-cell ratio.
Specific inhibitors were used in the following concentrations to suppress/neutralize ARG1, iNOS, heme oxygenase-1 (HO-1), cyclooxygenase-2 (COX-2), IDO, ROS, secreted TGF-b and IL-10: 500 mM N(o)-hydroxynor-arginine/nor-NOHA (Calbiochem, Bad Soden, Germany), 300 mM NGmonomethyl-L-arginine (L-NMMA; Sigma-Aldrich), 500 mM 1-methyl-DLtryptophan (1-MT; Sigma-Aldrich), 100 IU catalase (CAT; Sigma-Aldrich), 10 mg/ml neutralizing anti-TGF-b antibodies/aTGF-b (R&D Biosystems, Wiesbaden-Nordenstadt, Germany), 5 mg/ml anti-IL-10 antibodies/aIL-10 (R&D Biosystems), 50 mM tin protoporphyrin/SNPP (Frontier Scientific, Logan, UT, USA), and 10 mM NS398 (Cayman Chemicals, Ann Arbor, MI, USA), respectively.
Responder T cells were labeled with 2.5 mmol/l of CFSE. T-cell proliferation and CD3z-chain expression was assessed by flow cytometry, IFN-g production in the supernatants by ELISA.
Cell death assessment
Cell death was determined by 7-amino-actinomycin D (7-AAD; Biolegend, San Diego, CA, USA) and FITC-conjugated annexin-V (Biolegend) costaining. 7-AAD À annexin-V À double negative cells were considered vital.
Antibodies and flow cytometry 
Quantitative PCR
Total RNA was extracted from purified CD14 þ HLA-DR neg/low cells using the RNeasy mini kit (Qiagen, Hilden, Germany) followed by its reverse transcription to cDNA (Superscript II reverse transcriptase; Invitrogen). mRNA levels were quantified by real-time quantitative PCR using PCR Brilliant III Ultrafast SYBR Green (Agilent Technologies, Bö blingen, Germany) and a Step One real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). Relative gene expression was determined by normalizing the expression of each target gene to b-actin. Gene-specific primers are detailed in the Supplementary (Figure 1aii ) up to 6 months following transplantation (HD: 4.31±4.59%; months after allo-HSCT, 1-3: 19.26 ± 18.22%; 3-6: 15.68 ± 15.14%) and declined to 7.89 ± 7.10% HLA-DR neg/low cells among monocytic cells in the samples retrieved 6-12 months after allo-HSCT (Figure 1bii ). Both phenomena contributed significantly (Supplementary Figure 2) to the observed substantial accumulation of circulating CD14
þ HLA-DR neg/low cells in patients (HD: 0.40 ± 0.36%; months after allo-HSCT, 1-3: 5.34±8.74%; 3-6: 3.32±5.40%; 6-12: 1.80±2.46%) (Figure 1ci ).
Over time, we noticed a significant decrease of circulating CD14
þ HLA-DR neg/low cells in patients after allo-HSCT (observation time: day þ 26 to 379 post HSCT) (Figure 1cii ). This notion was further corroborated when looking at the serial samples of nine individual donors (months after allo-HSCT, 1-3: 6.16 ± 7.01%; 3-6: 2.17 ± 2.23%; 6-12: 1.83 ± 2.57%) ( Figure 1ciii ).
Next, we analyzed the phenotype of post-allo-HSCT CD14 þ HLA-DR neg/low cells ( Figure 1c ). The cells expressed myeloid markers (CD11c, CD33) and adhesion molecules (CD11b, CD62L), as well as receptors (TNF-receptor type 2/CD120b), associated with activation of myeloid cells. In support of their monocytic commitment, they were CD115 (also known as macrophage CSF (M-CSF) receptor) positive and showed accordingly the light and size scatter characteristics (data not shown). Interestingly, we found the expression of the scavenger receptor CD163, which is typical for M2-polarized monocytes. Furthermore, CD14
þ HLA-DR neg/low cells exhibited expression of co-stimulatory CD40 and CD80 molecules that have both been suggested to contribute to the inhibitory activity of myeloid suppressors by binding their cognate receptors on T cells. 27, 28 CD14 þ HLA-DR neg/low cells were negative for markers mainly found on granulocytes (CD15, CD66b), CD16 that is considered a marker for mature myeloid cells, 23 the IL-4 receptor a(CD124) and co-stimulatory CD86.
Chimerism was analyzed in the patients' peripheral bloodderived CD33 þ cell fraction (n ¼ 42), which contains the CD14 þ HLA-DR neg/low cells ( Figure 1d ) (in average 1.9 days after the evaluation of the CD14 þ HLA-DR neg/low cell frequency). As CD33 þ cells were in their majority donor-derived cells (median of 99.9% CD33 þ cells displayed donor chimerism), CD14
þ HLA-DR neg/low cells are most likely also donor derived in the majority of the studied samples (Supplementary Figure 3) .
CD14
þ HLA-DR low/neg cells in relation to other PBMC subsets
Output of CD14 þ HLA-DR neg/low cells depended on the degree of hematopoietic recovery, as it positively correlated with the absolute cell count of total leukocytes and polymorphonuclear leukocytes (granulocytes) (Figures 2a and b) .
A potential differentiation arrest of myeloid progenitors responsible for the observed accumulation of CD14 þ HLA-DR neg/low cells could also affect dendritic cells (DC). Therefore, we assessed the two major DC subsets: lineage 
ROS and response to activating stimuli in CD14
þ HLA-DR low/neg cells Aberrant myeloid cells often exhibit an increased production of ROS. 3 We compared the gene expression of several redox-relevant molecules in CD14 þ HLA-DR neg/low cells purified from allo-HSCT patients and HD, including anti-oxidants (superoxide dismutase type 2 (SOD2), HO-1 and CAT), key components of the ROSproducing NADPH oxidase (p47 phox and gp91 phox ) as well as a master transcription factor regulating over 100 cell-protective molecules (nuclear factor (erythroid-derived 2)-like 2 (Nrf2)). We found a significant upregulation of HO-1 and gp91 phox in the patients' cells ( Figure 3a) . Next, we evaluated the basal as well as the induced (upon PMA stimulation) ROS levels in both the groups without detecting any significant difference (Figure 3b) Figure 3c ) and a similar trend for pSTAT5 and pSTAT6. However, the responsiveness toward activating stimuli (IFN-a) was similar ( Figure 3d ).
Relationship between CD14
þ HLA-DR low/neg cells, cytokines and acute GVHD Several cytokines promote the accumulation, differentiation arrest and activation of immature myeloid cells. We measured numerous molecules including growth factors (for example, G-CSF), pro-inflammatory (for example, TNF-a) and immunomodulatory (for example, IL-10) cytokines in the patients' sera. We next compared the cytokine levels in patient samples with CD14 þ HLA-DR low/neg frequencies in the range (0.39±0.36%) of HDs (n ¼ 25) to patient samples with higher CD14
þ HLA-DR low/neg frequencies (n ¼ 36) (Figure 4a ). Patients with higher CD14 þ HLA-DR low/neg levels had a significantly (Pp0.05) increased amount of serum MIP-1b (44.92 ± 38.65 versus 26.53 ± 32.94 pg/ml), IL-15 (10.31 ± 11.01 versus 6.28 ± 2.35 pg/ml), IL-10 (19.48 ± 26.47 versus 7.91 ± 11.97 pg/ml), IL-6 (28.01 ± 47.26 versus 6.48 ± 9.87 pg/ml), IL-1b (9.49±16.82 versus 4.34±8.23 pg/ml) and G-CSF (211.50 ± 183.30 versus 119.70 ± 120.30 pg/ml). To further narrow down the cytokines involved, we performed a correlation analysis between the cytokines of interest (significant in the analysis shown in Figure 4a and in general increased when compared with HD levels (Supplementary Figure 4) ) and the corresponding CD14 þ HLA-DR low/neg frequencies of all patient samples. As shown in Figure 4b , only IL-6, IL-10 and G-CSF correlated positively with the CD14 þ HLA-DR low/neg cells. As G-CSF can be applied following allo-HSCT to promote myeloid reconstitution, we were interested in whether patients that received G-CSF at any time-point (n ¼ 20 samples; last G-CSF application in average 168 ± 128 days before analysis) had higher CD14 þ HLA-DR low/neg cell frequencies than untreated patients (n ¼ 41 samples). As depicted in Figure 4c , G-CSF administration had no influence on the CD14 þ HLA-DR low/neg cell frequency. In the samples collected within the first 100 days after allo-HSCT, the CD14 þ HLA-DR low/neg cell frequency was significantly higher in patients with a higher grade of acute GVHD (2-3) as compared with no or lower grade (0-1) GVHD (Figure 4d ). We could not detect differences regarding the cytokines tested in Figure 4b between these two groups (Supplementary Figure 5) .
CD14
þ HLA-DR low/neg cells suppress T-cell responses via IDO Similar to observations in non-Hodgkin's lymphoma patients, 17 the presence of CD14 þ HLA-DR low/neg cells correlated with a decreased lymphocyte count in allo-HSCT patients (Figure 5a ). Analyzing several circulating T-cell subsets, including their (Table 1) , revealed a negative correlation between HLA-DR þ
CD4
þ T cells (late activation) and CD14 þ HLA-DR low/neg cells (Table 2) . Then again, the proportion of activated CD25 þ NK cells was positively associated with the CD14 þ HLA-DR low/neg cell frequency (Table 3) .
The proliferative potential of stimulated purified T cells from allo-HSCT patients was decreased as compared with T cells from (Figure 5bi) . When T-cell-activating beads were added to PBMCs from allo-HSCT patients, the relative frequency of CD14 þ HLA-DR low/neg cells negatively correlated with T-cell proliferation as measured after 5 days (Figure 5bii) . Next, we performed T-cell suppression assays by co-culturing (in increasing ratios) purified CD14 þ HLA-DR low/neg cells from patients (at different time points after allo-HSCT) and HD with autologous T cells (Figure 5c ). CD14
þ HLA-DR low/neg cells from both patients and HD suppressed T-cell proliferation in a dose-dependent manner. Cells derived from patients were more potent suppressors, already effective at a 1:8 CD14
þ HLA-DR low/neg cell to T-cell ratio. In addition, we detected a tendency toward increased cell death among T cells when stimulated and co-cultured with autologous allo-HSCT CD14 þ HLA-DR low/neg cells (Supplementary Figure 6) . Next, we compared the gene-expression levels of several immunoregulatory molecules in allo-HSCT and HD CD14
þ HLA-DR low/neg cells (Figure 5d ). TGF-b, IL-10, COX-2 and IDO were significantly higher expressed in the patients' cells. There was no difference regarding the C/EBPb gene expression levels in CD14
þ HLA-DR neg/low cells derived from patients compared with HD (Figure 5e ).
To investigate the underlying mechanism, we blocked all candidate molecules evaluated in Figure 5d , as well as HO-1 (by SnPP) and oxidative stress (by CAT), as HO-1 and gp91 phox expression was increased in patients' cells (Figure 3a) . Only blocking of IDO by its competitive inhibitor 1-MT significantly enhanced T-cell proliferation (2.87-fold increase; P ¼ 0.03) (Figure 5f, Supplementary Figure 7) . As IDO affects cytokine production and CD3z-chain expression of T cells, 29 we assessed both upon addition of 1-MT. Inhibiting IDO significantly increased IFN-g (Figure 5g ) release and promoted T-cell CD3z-chain expression, which was also found to be decreased in allo-HSCT patients (Figure 5h ).
DISCUSSION
In this study, we report for the first time an increased frequency of circulating monocytic CD14
þ HLA-DR neg/low cells in patients after allo-HSCT. These cells had monocytic features and suppressed T-cell activity. 4 In accordance with previous reports about MDSCs of equivalent phenotype, 2,3,12,17 the cells co-expressed CD11b, CD33, CD115 (also known as M-CSF receptor), CD120b (also known as the TNF-a receptor type 2) and the co-stimulatory molecules CD40 and CD80. 28 The cell adhesion molecule CD62L has already been described in several types of MDSCs 30 and enables entry to secondary lymphoid organs thereby suppressing T-cell priming.
Increased ROS production has emerged as a typical characteristic for (especially granulocytic) MDSCs. 31 These highly reactive and permeable molecules contribute to their T-cell-suppressive activity. Furthermore, ROS triggers the activation STAT3 transcription factor that regulates MDSC expansion. 3, 7, 11 Increased activity of the membrane-bound NADPH oxidase (NOX) enhanced ROS production in MDSCs. Upregulation of NOX subunits such as p47 phox or gp91 phox have been described in MDSCs.
3,11 Although we found higher gp91 phox levels in the patient CD14
þ HLA-DR low/neg cells, ROS measurements before and after stimulation were similar in patients and healthy controls. Interestingly, HO-1, a stress-responsive multifunctional molecule with strong anti-oxidative properties, was elevated in the patient CD14 þ HLA-DR low/neg cells, in agreement with findings from a preclinical sepsis model. 32 At this point we might speculate that CD14 þ HLA-DR low/neg cells in allo-patients antagonize an increase in NOX activity by upregulating cytoprotective molecules (for example, HO-1 or CAT). HO-1 has immunoregulatory functions þ HLA-DR low/neg cellmediated T-cell suppression. Owing to the limited cell numbers, we were not able to assess in vitro Treg induction. 12, 18 Our ex vivo data did not indicate any association between circulating frequencies of CD14 þ HLA-DR low/neg cells and Tregs, including the naturally occurring IL-10 þ (Tr1) and TGF-b þ (Th3) subsets. Activation of STAT1 represents an early step in monocyte maturation and is an important component of tumor-associated MDSC suppression. 34 Similar to the reports in B-cell non-Hodgkin's lymphoma, 17 we found a decreased baseline STAT-1 activation (that is, phosphorylation) in the patient CD14 þ HLA-DR low/neg cells. As STAT-1 activation is linked to the activation of Arg1 and iNOS, low baseline levels of STAT-1 could partly explain the lack of Arg1 and iNOS upregulation. Signaling through the IL-4 receptor a-chain (IL-4Ra) (also known as CD124) after binding IL-4 or IL-13 leads to STAT-6 activation in MDSCs, accompanied by induction of Arg1 expression. 35 The patient CD14 þ HLA-DR low/neg cells were negative for CD124 and furthermore showed a tendency toward lower STAT-6 activation. STAT-3 that is involved in MDSC expansion was at physiological levels and all assessed STAT transcription factors exhibited a regular IFN-a responsiveness.
Levels of CD14 þ HLA-DR low/neg cells steadily decreased over time, implying that events around the time-point of transplantation might be responsible for the early increase. Abundance of (myeloid) growth factors (for example, G-CSF or M-CSF) in conjunction with inflammatory cytokines (for example, IL-6 or TNF-a) promote myeloid expansion, differentiation arrest and 'activation' of suppressive properties, finally resulting in CD14 þ HLA-DR low/neg cell accumulation. [5] [6] [7] Pretransplant conditioning, HSC-infusion and subsequent immune reactions generate a socalled 'cytokine storm' in allo-HSCT patients. 36 We found several putative MDSC-promoting cytokines to be increased in our patients. The proportion of CD14 þ HLA-DR low/neg cells correlated significantly with G-CSF and IL-6. Both have previously been shown to induce MDSCs from monocytes 6, 7 as well as from bone marrow-derived hematopoietic precursors, 5 and are involved in the differentiation arrest of myeloid cells in cancer patients. Cytokine levels that were found to significantly differ between both the groups were further analyzed by correlating cytokine levels with the CD14 þ HLA-DR low/neg cell frequencies in all allo-HSCT patient samples (n ¼ 51). (c) Levels of the CD14 þ HLA-DR low/neg cell frequency were compared between allo-HSCT patients that had received G-CSF treatment during the post-allo-HSCT period and untreated patients. (d) Levels of the CD14 þ HLA-DR low/neg cell frequency were compared between allo-HSCT patients with acute GVHD grade 0-1 and 2-3. The n indicates the sample number; columns represent mean values and bars the standard error mean; NS, not significant; *P-valuep0.05.
þ HLA-DR low/neg cell frequency. In fact, MDSCs produced IL-10 (data not shown) and exhibited increased mRNA transcripts as compared with their HD counterparts. This is in line with observations from MDSCs with a similar CD14 þ HLA-DR 
CD14
þ HLA-DR low/neg cell levels correlated positively with the absolute leukocyte and granulocyte count in support of our current understanding that MDSCs can originate within the 'emergency myelopoiesis' as seen in infections. 41 Similarly, the post-transplant period is characterized by an abundance of pro-inflammatory stimuli and available space in the bone marrow niche. Myeloid cells are also the first to reconstitute after allo-HSCT. 22 This agrees with our observations of the CD14 þ HLA-DR low/neg cell-kinetics after allo-HSCT, which partly result from the relative increase of circulating monocytic cells as noted in previous studies. 25 Systemic administration of G-CSF to enhance granulopoiesis promoted monocytes that suppressed T-cell allo-activation. 42 Frequency of CD14 þ HLA-DR neg/low cells 
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was not altered by G-CSF treatment, which is in line with a previous report showing that HLA-DR levels on CD14 þ cells remained stable before and shortly after G-CSF application. 42 DC differentiation arrest has been shown to yield in MDSC accumulation in cancer models. 43 Furthermore, recent in vitro observations suggest that even reprogramming of DCs toward stable MDSCs might contribute to their increase. 44 The proportion of pDCs but not mDCs correlated negatively with CD14 þ HLA-DR low/neg cells. It may be speculated that differences in the ontogeny of both DC subsets might explain this finding. Common lymphoid and myeloid progenitors both generate pDCs.
14 Under steady state conditions, pDCs are predominantly of myeloid origin but may switch toward lymphoid origin during severe inflammation (that is, GVHD). 45 Although 'emergency' myelopoiesis leads to increased levels of peripheral CD14 þ HLA-DR low/neg cells, pDC differentiation (from lymphoid precursors) might be impaired. This would also be in line with the inverse correlation of CD14 þ HLA-DR low/neg cells and the absolute lymphocyte count, and warrants further in depth investigations in preclinical as well as in vitro models (for example, impact of CD14 þ HLA-DR low/neg cells on differentiation of hematopoietic progenitors). CD14 þ HLA-DR low/neg cells isolated from allo-patients inhibited T-cell activation and exhibited-in agreement with findings in malignant melanoma-3 a stronger per cell suppressive potency as compared with their healthy control counterparts. Several immunoregulating molecules were more highly expressed in the allo-CD14
þ HLA-DR low/neg cells (namely, COX-2, IDO, IL-10 and TGF-b), but not iNOS and Arg1, both of which metabolize L-arginine and are linked to MDSC function. 1 We evaluated a broad array of inhibitors for all tested suppressive molecules including ROS and HO-1, and found only IDO to be significantly involved in CD14 þ HLA-DR low/neg cell-mediated T-cell suppression, which is in line with previous observations on the whole monocyte compartment. 25 COX-2 expression, although increased, did not contribute to the T-cell suppressive action of the CD14 þ HLA-DR low/neg cells. Remarkably, recent data suggest that MDSC-derived endogenous PGE 2 sustains their immature and suppressive phenotype by forming an autocrine feedback loop. 44 MDSCs generated in vitro by IL-6 and G-CSF treatment express IDO, 6, 7 and both cytokines promote IDO expression and activity in myeloid cells in vivo. 46, 47 As mentioned previously, serum levels of IL-6 and G-CSF correlated positively with the CD14 þ HLA-DR low/neg cell frequency in the allo-HSCT patients. IDO is an enzyme that catabolises tryptophan into kynurenine. Both, tryptophan depletion and kynurenine accumulation induce immunoregulatory effects leading among others to T-and NK-cell dysfunctions, and Treg induction. 29 Inhibition of IDO in CD14 þ HLA-DR low/neg cells led to an increased IFN-g production and CD3z-chain expression in T cells. Reduction of CD3z has been previously described in the context of MDSC-mediated effects. 23 In addition, CD14
þ HLA-DR low/neg cell levels were associated with a lower proportion of circulating activated HLA-DR þ CD4 þ T cells. This cell population is more prone to undergo apoptosis after allo-HSCT. 48 
CD14
þ HLA-DR low/neg cell levels correlated with activated CD25 þ NK-cell proportions. Murine MDSCs express RAE-1, a ligand for the activating NKG2D receptor on NK cells. 49 Clearly, this interaction requires further investigation, as reports on MDSC-NK-cell interactions remain controversial.
As both T-cell proliferation and CD3z chain expression are attenuated in patients following allo-HSCT, it is possible that CD14 þ HLA-DR low/neg cells contribute via IDO to these T-cell alterations. 29 IDO 25 and MDSCs 50 induce apoptosis in activated lymphocytes. When co-culturing activated T cells with autologous CD14 þ HLA-DR low/neg cells, we observed a tendency toward increased cell death. In conjunction with the T-cell suppressive effects exerted by the CD14 þ HLA-DR low/neg cells, this might explain the inverse correlation between CD14 þ HLA-DR low/neg cell frequency and lymphocyte count in the allo-HSCT patients. Although T-cell dysfunctions can diminish pathogen clearance and contribute to treatment-related mortality, they might also represent inherent protective mechanisms against hyperinflammation as occurs during GVHD. In vivo observations from preclinical GVHD models support the notion that MDSC expansion following HSCT controls allo-reactive T cells and prevents GVHD development. 19 Interestingly, recent findings in immunosuppressive, mesenchymal stromal cells showed that IDO in addition to its T-cell suppressive capacity enables them with pathogen-clearing properties, 51 which of course warrants further investigation in allo-HSCT CD14 þ HLA-DR low/neg cells. In our study group of limited sample size, we did not notice an increased risk (or benefit) regarding infectious complications (that is, sepsis and viral reactivations) in patients with high CD14 þ HLA-DR low/neg cell levels (data not shown).
The concept that MDSC accumulation is dictated by the state of inflammation in a stress-responsive manner 41 is further corroborated by our observations that CD14 þ HLA-DR low/neg cell frequency was higher in patients with more severe acute GVHD. Given their T-cell-suppressive function, this finding at first sight appears contradictory but might reflect their reactive increase, which obviously is not sufficient to balance immune responses in severe, established GVHD. This is in line with recent observations from Landfried et al. 24 showing that the overall IDO activity in patients depends on the GVHD grade, which they ascribed to an immunoregulatory loop formed by IDO and IFN-g. It is possible that this feedback mechanism also includes additional pro-inflammatory cytokines (IL-6 and G-CSF) and other yet unidentified factors that promote the expansion of IDO þ
þ HLA-DR low/neg cells. However, the potential impact of an immunosuppressive treatment on CD14 þ HLA-DR low/neg cells in case of severe GVHD has to be taken into consideration. Data from mice indicated that glucocorticoids-the treatment of choice in GVHDpromote suppressive monocytes resembling MDSCs. 52 In future studies, it will be very interesting to systematically investigate in more homogenous (regarding the immunosuppressive prophylaxis/treatment) patient groups the impact of such immunomodulating intervention on CD14 þ HLA-DR low/neg cell levels.
The idea that MDSCs represent an intrinsic antagonist of GVHD is appealing, especially in view of therapeutic interventions similar to Treg-and MSC-based cell therapies. Adoptive MDSC transfer efficiently ameliorates alloreactivity in preclinical GVHD models. 14, 21, 47 As T-cell reactivity also controls the GVT effects, it will be necessary to determine the role of MDSC expansion for disease relapse. We therefore plan to conduct a prospective study on a larger patients cohort that will allow a multivariate risk assessment. As yet, results from preclinical studies investigating MDSC transfer indicate efficient GVHD prevention without compromising GVT. 14, 21 In conclusion, we provide evidence that suppressive monocytic cells expand after allo-HSCT. They display the CD14 þ HLA-DR neg/low phenotype and T-cell suppressive activity of the monocytic MDSCs identified in malignant diseases 3, 12, 13, 16, 17 but utilize different regulatory mechanisms (namely IDO) underscoring the MDSC-heterogeneity. Our data indicates that the inflammatory response that occurs after allo-HSCT contributes to the CD14 þ HLA-DR low/neg cell expansion. It remains to be elucidated in future prospective studies whether CD14 þ HLA-DR low/neg cells impact long-term GVHD and GVT responses and overall survival to validate their role as a novel therapeutic target.
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